Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03253913
Other study ID # 2016-4904
Secondary ID 1R34HL138235-01
Status Completed
Phase Phase 2
First received
Last updated
Start date March 31, 2018
Est. completion date October 15, 2022

Study information

Verified date January 2023
Source University of Cincinnati
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

RESULT is a phase II dose-escalating, open-label, safety and efficacy study to determine if there is a potential benefit of resveratrol in combination with sirolimus in patients with lymphangioleiomyomatosis (LAM). The primary study objective is to assess the change in serum vascular endothelial growth factor-D (VEGF-D) level after 24 weeks of treatment with a combination of resveratrol and sirolimus as compared to the VEGF-D level in patients on a stable dose of sirolimus alone. The secondary objectives of this study include an assessment of the safety and adverse effect profile of combined resveratrol and sirolimus in adult patients with LAM, and to determine the effect of treatment with a combination of resveratrol and sirolimus on changes in lung function and quality of life.


Description:

Study Design RESULT was an open label, dose-escalation, phase 2 study with longitudinal repeated measures. In order to be eligible for trial inclusion, patients had to satisfy all of the following criteria: 1) confirmed diagnosis of LAM per the American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines14, 2) age ≥18 years with signed informed consent, 3) on sirolimus for at least 20 weeks, and 4) VEGF-D stabilization as demonstrated by two stable values post initiation of sirolimus and drawn at least 12 weeks apart from each other. Key exclusion criteria included inability to provide consent, active listing for lung transplantation, enrolled in another interventional clinical trial, known allergy or hypersensitivity to resveratrol, and current or planned pregnancy in the next six months. RESULT was a single site study conducted at the University of Cincinnati (UC). Study enrollment was open to LAM patients throughout the United States with travel reimbursement provided through the study. The study was reviewed and approved by UC's Institutional Review Board (IRB 2016-4904). An independent Data and Safety Monitoring Board (DSMB) was convened and met every six months to ensure the safety of study participants. All subjects provided written informed consent prior to the conduct of any study related activity. Outcome Measures The primary objective of this study was to assess the change in serum VEGF-D value after 24 weeks of treatment with a combination of resveratrol and sirolimus, as compared to the historical VEGF-D values of patients prior to the study on sirolimus alone. Serial assessments of serum VEGF-D, pulmonary function tests (PFTs), treatment related adverse effects (AEs), complete blood count, liver and renal function tests, and HRQOL were performed at baseline and at 8, 16, and 24 weeks. In addition, sirolimus trough levels, measured 24 +/- 4 hours following the last dose, were assessed at baseline and at weeks 2, 4, 8, 12, 16, 18, 20 and 24. VEGF-D quantification was performed at the Translational Trial Development and Support Laboratory based at Cincinnati Children's Hospital Medical Center in a College of American Pathologists (CAP)/Clinical Laboratory Improvement Amendments (CLIA) approved manner. All other laboratory assessments were performed via Quest Diagnostics. HRQOL was measured by using four validated scales: St. George's Respiratory Questionnaire (SGRQ), University of California San Diego Shortness of Breath score (SDSOB), EuroQol visual analogue scale (EQVAS), and A Tool to Assess Quality of Life in LAM (ATAQ-LAM). Study Drug Resveratrol used in this study was obtained from Evolva and manufactured by fermentation using genetically modified yeast in a process that results in trans-resveratrol with a purity of at least 98%, and packaged into capsules with each capsule containing 125mg resveratrol. The capsules were independently verified for content by mass spectrometry performed at UC and for sterility by microbial testing at Q Laboratories Inc., Cincinnati. Investigational new drug (IND) designation for studying Resveratrol in this trial was obtained from the United States Food and Drug Administration (FDA): IND 131722; IND Sponsor: N. Gupta. Resveratrol was administered in a stepwise dose escalating fashion at 8-week intervals with assessment of VEGF-D, PFTs, AEs, and HRQOL prior to each dose escalation. The starting dose of resveratrol was 250mg once daily for the first 8 weeks, followed by 500mg daily from Weeks 8 - 16, and 500mg twice daily for the last 8 weeks (Weeks 16 - 24), with provisions for dose reduction if necessitated by AEs. Treatment related AEs were tabulated using the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) version 4.


Recruitment information / eligibility

Status Completed
Enrollment 25
Est. completion date October 15, 2022
Est. primary completion date October 15, 2022
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: Subjects enrolled in the trial must meet all of the following criteria. 1. Definitive diagnosis LAM based on the presence of characteristic cystic change on high-resolution computed tomography (HRCT) of the chest. The diagnosis must be confirmed by one of the following: A) Histopathological confirmation by biopsy (lung, abdominal mass, lymph node or kidney or cytology from thoracic or abdominal sources revealing human melanoma black-45 (HMB45)+ staining of spindled/epithelioid cells) B) Compatible chest CT scan findings in the setting of tuberous sclerosis, angiomyolipomas (diagnosed by CT, magnetic resonance imaging (MRI) by the site radiologist or biopsy) or chylous pleural effusion (verified by tap) C) Chest CT scan findings compatible with LAM and a VEGF-D level = 800pg/ml. 2. Age 18 years or greater. 3. Signed and dated informed consent 4. Currently on sirolimus for treatment of LAM for at least 20 weeks 5. Evidence of disease stabilization on sirolimus as demonstrated by two stable values of serum VEGF-D post initiation of sirolimus drawn at least 12 weeks apart from each other. For the purpose of this study, a variation in serum VEGF-D of less than or equal to 15% is considered stable. Exclusion Criteria: - Subjects who meet any of the following criteria are not eligible for enrollment as study participants: 1. Known allergy or hypersensitivity to Resveratrol 2. Inability to provide informed consent 3. Active enrollment in other clinical drug trials for LAM 4. Pregnant or plan to become pregnant in the next 6 months 5. Breast feeding 6. Inability to comply with pulmonary function tests or follow up visits 7. Inadequate contraception 8. Use of estrogen containing medications within the 30 days prior to randomization 9. History of organ transplant 10. Actively listed for lung transplantation 11. Inability to comply with study procedures or attend scheduled study visits 12. Any clinically significant medical disease (other than LAM) that is associated with an expected survival of less than 2 years, or likely to impact the ability of the patient to participate in the study in the opinion of the investigator, or impact the study efficacy or safety assessments.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Sirolimus
Patients will have been on a stable dose of sirolimus prior to enrolling and will continue that throughout the study.
Resveratrol
Escalating doses of resveratrol will be given throughout the study. Patients will start at 250mg daily for 8 weeks, followed by 500mg daily for 8 weeks, and 500mg BID for the last 8 weeks.

Locations

Country Name City State
United States University of Cincinnati Cincinnati Ohio

Sponsors (2)

Lead Sponsor Collaborator
University of Cincinnati National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Serum Vascular Endothelial Growth Factor-D (VEGF-D) Levels After Treatment With a Combination of Resveratrol and Sirolimus as Compared to Baseline Serum VEGF-D Levels on Sirolimus Alone Change in serum VEGF-D level in pg/ml after treatment with a combination of resveratrol and sirolimus as compared to the historical VEGF-D level in patients on a stable dose of sirolimus alone. Baseline VEGF-D values represent serum VEGF-D levels on stable dose of sirolimus alone prior to starting study drug. Baseline, Week 8, Week 16, Week 24
Secondary Number of Treatment-Emergent Adverse Events Safety and adverse effect profile of combined resveratrol and sirolimus in adult patients with LAM Baseline, Week 8, Week 16, Week 24
Secondary Change in Forced Expiratory Volume in One-second (FEV1) After 24 Weeks of Combined Treatment With Resveratrol and Sirolimus Difference in the absolute Forced expiratory volume in one-second (FEV1) after 24 weeks of treatment. FEV1 values reported are in liters. There are no definite minimum and maximum values of FEV1 as it is a physiological measure of lung function and varies from individual to individual. Higher FEV1 scores indicate better lung function. Baseline, Week 8, Week 16, Week 24
Secondary St. George's Respiratory Questionnaire (SGRQ) Quality of Life Assessment Scores After Treatment With Combined Resveratrol and Sirolimus Quality of life scores will be calculated by using SGRQ to determine if the combination of resveratrol and sirolimus can improve the quality of life in patients with LAM. This is a disease-specific instrument designed to measure impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease. Scores range from 0 to 100, with higher scores indicating worse quality of life. Baseline, Week 8, Week 16, Week 24.
Secondary Scores on "A Tool to Assess Quality of Life in LAM (ATAQ-LAM) Quality of Life Assessment" Scale After Treatment With 24 Weeks of Resveratrol and Sirolimus Quality of life scores will be calculated by using ATAQ-LAM to determine if the combination of resveratrol and sirolimus can improve the quality of life in patients with LAM. A Tool to Assess Quality of Life in LAM (ATAQ-LAM) is a disease-specific instrument designed to assess HRQOL in patients with LAM, and consists of 32 items divided into 4 domains: exertional dyspnea, cough, fatigue, and emotional well-being. The total scores on this scale can range between 32 - 192, with higher scores indicating worse quality of life. Baseline, Week 8, Week 16, Week 24
Secondary San Diego Shortness of Breath Score (SD-SOB) Quality of Life Assessment Scores After Treatment With 24 Weeks of Resveratrol and Sirolimus The San Diego shortness of breath questionnaire measures the quality-of-life impairment secondary to dyspnea resulting from pulmonary disorders. It is a 24-item measure that assesses self-reported shortness of breath while performing a variety of activities of daily living, with higher scores indicating worse quality of life. Baseline, Week 8, Week 16, Week 24
Secondary EuroQOL Visual Analogue Scale (EQ-5D) Scores After Treatment With 24 Weeks of Sirolimus and Resveratrol. The EuroQOL visual-analogue scale (EQVAS) measures self-reported ratings of health status. Scores range from 0 to100, with lower scores indicating worse functioning. Baseline, Week 8, Week 16, Week 24
See also
  Status Clinical Trial Phase
Completed NCT01687179 - Safety Study of Sirolimus and Hydroxychloroquine in Women With Lymphangioleiomyomatosis Phase 1
Completed NCT00366509 - Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases
Completed NCT00552955 - Effect of Fasting on the Size of Abdominal Lymphatic Tumors in Women
Unknown status NCT00490789 - Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM Phase 2
Not yet recruiting NCT05087134 - Characterizing LAM With 11C-Choline PET/CT Early Phase 1
Completed NCT02009241 - Pulmonary Rehabilitation in Lymphangioleiomyomatosis N/A
Recruiting NCT05190627 - Effect of Loratadine in Lymphangioleiomyomatosis Phase 2
Completed NCT05323370 - Lymphangioleiomyomatosis, a Study on Cathepsin K
Completed NCT02859194 - The Effect of Lt to Rt Shunt Using Veno-veno-arterial Extracorporeal Membrane Oxygenation (ECMO) on Coronary Oxygenation in Lung Transplantation Patients N/A
Completed NCT01353209 - Letrozole for Lymphangioleiomyomatosis Phase 2
Recruiting NCT02432560 - Safety and Durability of Sirolimus for Treatment of LAM
Completed NCT02061397 - Safety of Simvastatin in LAM and TSC Phase 1/Phase 2
Active, not recruiting NCT01552434 - Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease Phase 1
Recruiting NCT04577937 - Sleep Patterns in Patients Affected by Lymphangioleiomiomatosis N/A
Completed NCT00005906 - Treatment With Octreotide in Patients With Lymphangioleiomyomatosis Phase 2
Recruiting NCT01799538 - Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis Phase 1/Phase 2
Completed NCT00989742 - Doxycycline In Lymphangioleiomyomatosis (LAM) Phase 4
Recruiting NCT06160310 - Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)
Enrolling by invitation NCT05727852 - Breath Analysis and Arterial Stiffness in Patients With Respiratory Diseases
Completed NCT03131999 - LAM Pilot Study With Imatinib Mesylate Phase 1/Phase 2